0001209191-20-065185.txt : 20201228 0001209191-20-065185.hdr.sgml : 20201228 20201228164021 ACCESSION NUMBER: 0001209191-20-065185 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201222 FILED AS OF DATE: 20201228 DATE AS OF CHANGE: 20201228 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Zinda Michael CENTRAL INDEX KEY: 0001815366 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39335 FILM NUMBER: 201418793 MAIL ADDRESS: STREET 1: C/O REPARE THERAPEUTICS INC. STREET 2: 7210 FREDERICK-BANTING, SUITE 100 CITY: ST-LAURENT STATE: A8 ZIP: H4S 2A1 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Repare Therapeutics Inc. CENTRAL INDEX KEY: 0001808158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: Z4 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7210 FREDERICK-BANTING, SUITE 100 CITY: ST-LAURENT STATE: A8 ZIP: H4S 2A1 BUSINESS PHONE: (857) 412-7018 MAIL ADDRESS: STREET 1: 7210 FREDERICK-BANTING, SUITE 100 CITY: ST-LAURENT STATE: A8 ZIP: H4S 2A1 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-12-22 0 0001808158 Repare Therapeutics Inc. RPTX 0001815366 Zinda Michael C/O REPARE THERAPEUTICS INC. 7210 FREDERICK-BANTING, SUITE 100 ST-LAURENT A8 H4S 2A1 QUEBEC, CANADA 0 1 0 0 EVP, Chief Science Officer Common Stock 2020-12-22 4 M 0 15706 1.637 A 100935 D Common Stock 2020-12-22 4 M 0 25606 2.062 A 126541 D Common Stock 2020-12-22 4 S 0 1612 34.00 D 124929 D Common Stock 2020-12-22 4 S 0 39700 33.36 D 85229 D Common Stock 2020-12-23 4 M 0 1976 1.637 A 87205 D Common Stock 2020-12-23 4 M 0 4771 2.062 A 91976 D Common Stock 2020-12-23 4 M 0 9488 2.425 A 101464 D Common Stock 2020-12-23 4 S 0 12556 33.48 D 88908 D Common Stock 2020-12-23 4 S 0 3679 34.26 D 85229 D Common Stock 2020-12-24 4 M 0 432 2.062 A 85661 D Common Stock 2020-12-24 4 S 0 432 33.14 D 85229 D Employee Stock Option (right to buy) 1.637 2020-12-22 4 M 0 15706 0.00 D 2027-12-04 Common Stock 15706 13832 D Employee Stock Option (right to buy) 2.062 2020-12-22 4 M 0 25606 0.00 D 2029-03-29 Common Stock 25606 60101 D Employee Stock Option (right to buy) 1.637 2020-12-23 4 M 0 1976 0.00 D 2027-12-04 Common Stock 1976 11856 D Employee Stock Option (right to buy) 2.062 2020-12-23 4 M 0 4771 0.00 D 2029-03-29 Common Stock 4771 55330 D Employee Stock Option (right to buy) 2.425 2020-12-23 4 M 0 9488 0.00 D 2029-12-16 Common Stock 9488 148466 D Employee Stock Option (right to buy) 2.062 2020-12-24 4 M 0 432 0.00 D 2029-03-29 Common Stock 432 54898 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.925 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3) and (4). The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.97 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.00 to $34.61 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.46 inclusive. Twenty-five percent (25%) of the shares subject to the option vested on June 22, 2018, and one thirty-sixth (1/36th) of the remaining shares subject to the option vested or shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date. Twenty-five percent (25%) of the shares subject to the option vested on March 29, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the option vested or shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date. Twenty-five percent (25%) of the shares subject to the option vested on December 16, 2020, and one thirty-ninth (1/39th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date. /s/ Steve Forte, Attorney-in-Fact 2020-12-28